Amgen's stock is in a sustained uptrend, with a 1-year price change of +20.98%, significantly outpacing the S&P 500's 20.63% gain. The current price of $363.39 sits at 72.5% of its 52-week range ($269.77–$391.29), indicating the stock is closer to its highs but not overextended, suggesting room for further upside if momentum persists. The 52-week low of $269.77 provides a strong support level, while the high of $391.29 represents key resistance. With a beta of 0.403, Amgen is significantly less volatile than the market, appealing for risk-averse investors seeking steady exposure to healthcare. Short-term momentum is mixed: the 1-month change of +7.60% is strong and accelerating, while the 3-month change of +3.52% lags the S&P 500's 11.11% gain, indicating a recent relative underperformance. The 1-month relative strength of +3.53% versus the S&P 500 suggests a recent pickup, but the 3-month relative strength of -7.59% highlights a period of weakness. This divergence could signal a short-term reversal attempt, but confirmation is needed. The 52-week low of $269.77 serves as critical support, while the 52-week high of $391.29 is the immediate resistance. A breakout above $391.29 would signal a resumption of the uptrend, targeting new highs, while a breakdown below $269.77 would indicate a bearish reversal. With a beta of 0.403, Amgen is 60% less volatile than the S&P 500, making it a lower-risk holding in a portfolio.

Amgen's revenue trajectory is solidly growing, with Q4 2025 revenue of $9.896 billion, up 8.91% year-over-year from $9.086 billion in Q4 2024. The trailing twelve-month revenue trend shows acceleration from $8.149 billion in Q1 2025 to $9.896 billion in Q4 2025, driven by key products like Prolia ($1.054B), Otezla ($625M), and Evenity ($599M), as well as newer launches Tezspire ($474M) and Tepezza ($457M). The Horizon acquisition is contributing to growth, though the Tavneos safety concerns pose a risk. Profitability is robust, with Q4 2025 net income of $1.333 billion and a net margin of 13.47%, though this is down from 33.65% in Q3 2025 due to higher operating expenses. Gross margin remains strong at 81.91% in Q4 2025, reflecting Amgen's pricing power in biologics. Operating margin of 39.83% is healthy, but the net margin compression from Q3 to Q4 warrants monitoring. Amgen's balance sheet is leveraged but manageable, with a debt-to-equity ratio of 6.31 and a current ratio of 1.14. Free cash flow (FCF) was $961 million in Q4 2025, bringing TTM FCF to $8.1 billion, which comfortably covers the $1.283 billion quarterly dividend. ROE is exceptionally high at 89.06%, driven by leverage, while ROA of 8.35% indicates efficient asset use. The high debt load is a risk, but strong cash generation supports debt service.